Modeling Human Gamma Delta T Cells as Antitumor Agents In Vivo
Technical Report,01 Aug 2018,31 Jul 2019
University of Wisconsin Madison United States
Pagination or Media Count:
The central objective of this project is to provide mechanistic data that will support the development of human Vgamma9Vdelta2 T cells as an anti-tumor cellular immunotherapy for lymphomas driven by Epstein-Barr virus EBV infection. During this research period we have concluded our efforts on Major Task 1 and made progress on Major Tasks 2, 3, and 4. The most significant findings were i the observation that our gamma delta T immunotherapy cells express the CD16 receptor and can therefore mediate antibody-dependent cell-mediated cytotoxicity ADCC ii identification of a new live cell imaging methodology to perform screening and optimization experiments that will make our studies more efficient and reduce our animal usage iii preliminary experimental results demonstrating effector responses by the gamma delta T immunotherapy cells against EBV-infected B lymphocytes, that suggest that the EBV-infected B cells have upregulated their production of key endogenous ligands that allow for TCR-mediated recognition of target cells by gamma delta T cells without the need for added drugs.
- Medicine and Medical Research